Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 312 Records) |
| Query Trace: Colorectal Neoplasms and NRAS[original query] |
|---|
| Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer. Archives of medical science : AMS 2022 9 18 (5): 1221-1230. Bo?yk Aleksandra, Krawczyk Pawe?, Reszka Katarzyna, Krukowska Kinga, Kolak Agnieszka, Ma?dziuk S?awomir, Wojas-Krawczyk Kamila, Ramlau Rodryg, Milanowski Janu |
| Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 8 41 (3): 485-496. Topham James T, O'Callaghan Chris J, Feilotter Harriet, Kennecke Hagen F, Lee Young S, Li Weimin, Banks Kimberly C, Quinn Katie, Renouf Daniel J, Jonker Derek J, Tu Dongsheng, Chen Eric X, Loree Jonathan |
| Liquid biopsy for KRAS, NRAS and BRAF mutation testing in advanced colorectal cancer patients: the Argentinean experience. Future oncology (London, England) 2022 8 18 (29): 3277-3287. Güttlein Leandro, Luca María R, Esteso Federico, Fresno Cristóbal, Mariani Javier, Otero Pizarro Mercedes, Brest Esteban, Starapoli Solange, Kreimberg Kevin, Teves Paula, Mendoza Bertelli Andrea, R Girotti María, Salanova Ruben, O'Connor Juan |
| Predictive value of KRAS/NRAS, IL-4 VNTR and HPV alterations in metastases of colorectal cancer. Bratislavske lekarske listy 2022 123 (10): 758-768. Ozen Filiz, Yegin Zeynep, Avsar Cumhur, Zenginkinet Tulay, Koc Haydar, Ulasoglu Cel |
| Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study. Gene 2022 Aug 834 146646. Baba Omar, Bidikian Aram, Mukherji Deborah, Shamseddin Ali, Temraz Sally, Fakhruddin Najla, Khazzouh Mira, Ghizzawi Diana, Abdel Khalek Rabab, Zaatari Ghazi, Mahfouz Ra |
| Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors. Therapeutic advances in medical oncology 2022 6 14 17588359221105022. Xu Ting, Wang Xicheng, Wang Zhenghang, Deng Ting, Qi Changsong, Liu Dan, Li Yanyan, Ji Congcong, Li Jian, Shen L |
| Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer. British journal of cancer 2022 Jun . Hashimoto Taiki, Takayanagi Daisuke, Yonemaru Junpei, Naka Tomoaki, Nagashima Kengo, Yatabe Yasushi, Shida Dai, Hamamoto Ryuji, Kleeman Sam O, Leedham Simon J, Maughan Timothy, Takashima Atsuo, Shiraishi Kouya, Sekine Shige |
| Multivariate Risk Analysis of RAS, BRAF and EGFR Mutations Allelic Frequency and Coexistence as Colorectal Cancer Predictive Biomarkers. Cancers 2022 Jun 14 (11): . Ionescu Adriana, Bilteanu Liviu, Geicu Ovidiu Ionut, Iordache Florin, Stanca Loredana, Pisoschi Aurelia Magdalena, Miron Adrian, Serban Andreea Iren, Calu Valent |
| Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO open 2022 6 7 (3): 100512. Sunakawa Y, Satake H, Usher J, Jaimes Y, Miyamoto Y, Nakamura M, Kataoka M, Shiozawa M, Takagane A, Terazawa T, Watanabe T, Ishiguro K, Tanaka C, Takeuchi M, Fujii M, Danenberg K, Danenberg P V, Lenz H-J, Sekikawa T, Ichikawa |
| An innovative single-base extension method for synchronous detection of point mutations and MSI status in colorectal cancer. Cancer medicine 2022 12 . Liang Li, Li Xin, Nong Lin, Cai Weijing, Zhang Jixin, Liu Ping, Li Ti |
| Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer. Clinical colorectal cancer 2022 12 . Ten Hoorn Sanne, Mol Linda, Sommeijer Dirkje W, Nijman Lisanne, van den Bosch Tom, de Back Tim R, Ylstra Bauke, van Dijk Erik, van Noesel Carel J M, Reinten Roy J, Nagtegaal Iris D, Koopman Miriam, Punt Cornelis J A, Vermeulen Lou |
| The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis. BMC medical genomics 2022 12 15 (1): 259. Zhang Min, Meng Lei, Zhang Zhaoxuan, Wu Jing, Chen Xi, Wang Yuejing, He J |
| Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. Journal of cancer research and therapeutics 2022 12 18 (Supplement): S347-S353. Erol Cihan, Nahit Sendur Mehmet Ali, Bilgetekin Irem, Garbioglu Duygu Bayir, Hamdard Jamshid, Akbas Sinem, Hizal Mutlu, Arslan Cagatay, Sevinc Alper, Kucukarda Ahmet, Erdem Dilek, Kahraman Seda, Cakir Emre, Demirkiran Aykut, On Sercan, Dogan Izzet, Erdogan Atike Pinar, Koca Sinan, Kubilay Pinar, Eren Orhan Onder, Cilbir Ebru, Celik Emir, Araz Murat, Ozyukseler Deniz Tataroglu, Yildirim Mahmut Emre, Bahceci Aykut, Taskaynatan Halil, Oyman Abdilkerim, Deniz Gulhan Ipek, Menekse Serkan, Kut Engin, Gulmez Ahmet, Sakin Abdullah, Nayir Erdinc, Acar Ramazan, Sen Erdem, Inal Ali, Turhal Serdar, Kaya Ali Osman, Paydas Semra, Tastekin Didem, Hacibekiroglu Ilhan, Cincin Irfan, Bilici Ahmet, Mandel Nil Molinas, Dede Didem Sener, Akinci Muhammed Bulent, Oksuzoglu Berna, Uncu Dogan, Yalcin Bulent, Artac Mehm |
| Genetic and epigenetic characteristics of patients with colorectal cancer from Uruguay. Pathology, research and practice 2022 12 241 154264. Vital Marcelo, Carusso Florencia, Vergara Carolina, Neffa Florencia, Della Valle Adriana, Esperón Patric |
| Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa. BMC cancer 2022 11 22 (1): 1142. Jafari Meryem, Laraqui Abdelilah, Baba Walid, Benmokhtar Soukaina, Zaitouni Sara El, Ali Abdelmounaim Ait, Bounaim Ahmed, Moujahid Mountassir, Tanz Rachid, Mahfoud Tarik, Sbitti Yassir, Annaz Hicham El, Abi Rachid, Tagajdid Mohamed Rida, Kochri Safae El, Lahlou Idriss Amine, Hsaini Houda El, Belayachi Lamiae, Benjouad Abdelaziz, Ichou Mohammed, En-Nya Amina, Ennibi Khal |
| Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO precision oncology 2022 11 6 e2200191. Klute Kelsey A, Rothe Michael, Garrett-Mayer Elizabeth, Mangat Pam K, Nazemzadeh Reza, Yost Kathleen J, Duvivier Herbert L, Ahn Eugene R, Cannon Timothy L, Alese Olatunji B, Krauss John C, Thota Ramya, Calfa Carmen J, Denlinger Crystal S, O'Lone Raegan, Halabi Susan, Grantham Gina N, Schilsky Richard |
| Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. World journal of gastrointestinal oncology 2022 10 14 (9): 1654-1664. Valenzuela Guillermo, Burotto Mauricio, Marcelain Katherine, González-Montero Jai |
| [Laser microdissection for the analysis of molecular heterogeneity in colorectal cancer]. Pathologie (Heidelberg, Germany) 2022 10 43 (Suppl 1): 36-41. Maag Nathalie, Arndt Annette, Steinestel Konr |
| KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania. Medicine 2022 Oct 101 (40): e30979. Brinzan Costel Stelian, Aschie Mariana, Cozaru Georgeta Camelia, Deacu Mariana, Dumitru Eugen, Burlacu Ionut, Mitroi An |
| Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA oncology 2023 5 . Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Ferdinando De Vita, Lucia Altucci, Francesca Marrone, Fortunato Ciardiello, Teresa Troia |
| Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910. Cancer science 2023 5 . Dai Shida, Aya Kuchiba, Tatsuhiro Shibata, Tetsuya Hamaguchi, Satoshi Yamasaki, Masaaki Ito, Takaya Kobatake, Toru Tonooka, Tadahiko Masaki, Manabu Shiozawa, Yasumasa Takii, Hiroyuki Uetake, Shu Okamura, Hitoshi Ojima, Shinsuke Kazama, Hiroshi Takeyama, Keisuke Kanato, Yasuhiro Shimada, Yoshinori Murakami, Yukihide Kanemit |
| Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival. International journal of molecular sciences 2023 5 24 (9): . José María Sayagués, Juan Carlos Montero, Andrea Jiménez-Pérez, Sofía Del Carmen, Marta Rodríguez, Rosario Vidal Tocino, Enrique Montero, Julia Sanz, Mar Ab |
| Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF mutation status. Journal of cancer research and clinical oncology 2023 4 . Kang Sora, Lee Myung-Won, Song Ik-Chan, Lee Hyo-Jin, Yun Hwan-Jung, Jo Deog-Yeon, Kim Jung Sun, Kwon Jung Hye, Kim Ji-Yeon, Lee Kyung-Ha, Ryu Hyew |
| Different Clinicopathological Characteristics in Indonesian Colorectal Patients with NRAS Mutations and HER2 Over-Expression. Asian Pacific journal of cancer prevention : APJCP 2023 4 24 (4): 1373-1377. Kiki Lukman, Ade Tan Reza, Lisa Y Hasibuan, Yunia Sribudiani, Birgitta Maria Dewayani, Reno Rudiman, Etis Primastari, Prapanca Nugra |
| Epidemiological and molecular evaluation of BRAF, KRAS, NRAS genes and MSI in the development of colorectal cancer. Gene 2023 3 870 147395. Paula Simedan Vila Ana, Helena Rodrigues Gabriela, Leite Marzochi Ludmila, Garcia de Oliveira-Cucolo Juliana, Lívia Silva Galbiatti-Dias Ana, Felipe Maciel Andrade Rafael, de Santi Neto Dalísio, Gomes Netinho João, Castiglioni Lilian, Cristina Pavarino Érika, Maria Goloni-Bertollo E |
| Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study. Cell reports. Medicine 2023 3 100980. Niehues Jan Moritz, Quirke Philip, West Nicholas P, Grabsch Heike I, van Treeck Marko, Schirris Yoni, Veldhuizen Gregory P, Hutchins Gordon G A, Richman Susan D, Foersch Sebastian, Brinker Titus J, Fukuoka Junya, Bychkov Andrey, Uegami Wataru, Truhn Daniel, Brenner Hermann, Brobeil Alexander, Hoffmeister Michael, Kather Jakob Nikol |
| KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China. Medicine 2023 3 102 (9): e33115. Lian Shen-Yi, Tan Lu-Xin, Liu Xin-Zhi, Yang Lu-Jing, Li Ning-Ning, Feng Qing, Wang Ping, Wang Yue, Qiao Dong-Bo, Zhou Li-Xin, Sun Ting-Ting, Wang Lin, Wu Ai-Wen, Li Zhong- |
| KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients. Journal of clinical laboratory analysis 2023 3 e24868. Mirzapoor Abbasabadi Zohreh, Hamedi Asl Dariush, Rahmani Babak, Shahbadori Rozhin, Karami Sara, Peymani Amir, Taghizadeh Sara, Samiee Rad Fatem |
| Analysis Of Common Somatic Mutations In Colorectal Carcinoma And Associated Dysregulated Pathwaysarts. Journal of Ayub Medical College, Abbottabad : JAMC 2023 2 35 (1): 137-143. Hassan Sobia, Khatoon Ambrina, Bukhari Uzma, Mirza Tal |
| Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer. Genes, chromosomes & cancer 2023 2 . Wills Christopher, Watts Katie, Maughan Timothy S, Fisher David, Al-Tassan Nada A, Houlston Richard S, Escott-Price Valentina, Cheadle Jeremy |
- Page last reviewed:Feb 1, 2023
- Page last updated:May 22, 2023
- Content source: